시장보고서
상품코드
1320165

세계의 희소 신경질환 치료 시장 : 약제 등급별, 질환 유형별, 용도별, 국가별, 지역별 : 산업 분석, 시장 규모, 시장 점유율, 예측(2023-2030년)

Rare Neurological Disease Treatment Market with COVID-19 Impact Analysis, By Drug Class, By Disease Type, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 356 Pages | 배송안내 : 2-3일 (영업일 기준)


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

세계의 희소 신경질환 치료(Rare Neurological Disease Treatment) 시장 규모는 2022년 94억 3,530만 달러 규모에 달했습니다. 2023년부터 2030년까지 7.7%의 CAGR로 성장하여 확대될 전망입니다.

희귀 신경질환 치료 시장 - 시장 역학:

연구개발활동 활성화가 희소 신경질환 치료 수요를 촉진할 것으로 예측됩니다.

연구자, 의료 전문가, 제약 회사 및 환자 지원 단체 협력은 드문 신경 질환 치료제 창출을 촉진하는 데 필수적입니다. 환자 지원 단체는 연구를 촉진하고 지원하며 인지도를 높여 환자 결과와 치료 옵션을 개선합니다. 차세대 시퀀싱, 고처리량 스크리닝, 유전자 편집 방법과 같은 기술 진보는 특이한 신경 질환 실행 가능한 치료법 탐색과 개발을 가속화하고 있습니다. 연구자들은 이러한 기술 덕분에 치료 표적을 파악하고 완전히 새로운 약물을 개발하며 치료 전략을 개별화할 수 있습니다.

게노믹스와 분자생물학 발전은 특이한 신경질환에 관여하는 생물학적 유전학적, 분자생물학적 진전을 보다 잘 이해할 수 있게 되었습니다. 이 정보는 정밀의료 및 표적 치료제에 새로운 잠재를 제공합니다.

희소 신경질환 치료 시장 - 주요 통찰 :

  • 우리 연구 분석가가 공유한 분석에 따르면 세계의 희소 신경질환 치료 시장은 예측 기간(2023-2030년) 동안 약 7.7%의 CAGR로 매년 성장할 것으로 추정됩니다.
  • 희소 신경질환 치료산업은 동물 건강과 영양 관심 증가로 인해 현저한 속도로 성장할 것으로 예측됩니다.
  • 질병 유형별 알츠하이머병 분야는 2022년 최대 시장 점유율을 나타낼 것으로 예측됩니다.
  • 용도별로는 병원 약국 부문이 2030년 큰 시장 점유율을 차지할 것으로 예측됩니다.
  • 약물 등급별 항우울제 부문이 2022년 선도하였습니다.
  • 지역별로는 북미가 2022년 가장 큰 수익원이 되었습니다.

희소 신경질환 치료 시장 - 세분화 분석 :

세계의 희귀 신경 질환 치료 시장은 약물 등급, 질병 유형, 용도, 및 지역에 따라 세분화됩니다.

시장은 약물 등급에 따라 5가지 범주로 나뉩니다. 항우울제, 항 정신병 약물, 콜린에스테라아제 억제제, 생물학적 제제 등 시장을 독점하는 것은 항우울제 부문입니다. 질병 치료를 위한 항우울제 수요 증가가 시장 성장에 기여하고 있습니다.

시장은 질병 유형별 4가지로 분류됩니다 : 알츠하이머병, 나르코렙시, 경화증 등. 알츠하이머병 분야는 시장을 독점하고 있습니다. 알츠하이머병 유병률 증가는 시장 성장에 영향을 미칩니다.

시장은 용도별 세 가지 범주로 분류됩니다. 병원 및 클리닉, 수술센터 및 기타. 병원 약국 부문은 시장을 독점합니다. 병원 수준 신경 질환 치료 건수 증가는 이 부문 성장을 늘리고 있습니다.

희소 신경질환 치료 시장 - 지리적 분석:

지리적으로 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카으로 퍼져 있습니다. 이 지역은 비즈니스를 제공하는 국가에 의해 더 나뉩니다.

희소 신경질환 치료 시장 - 경쟁 구도 :

신경 질환 유병률이 상승하고 있으며, 희소 신경질환 치료 시장에 영향을 미치고 있습니다. 기업 웹사이트 및 제품 유형과 같은 여러 판매 채널이 솔루션 및 제품을 판매하기 위해 기업 사용됩니다. 제품은 기술, 제품 개발, 마케팅 등 다양한 요인들과 경쟁하고 있습니다. 리치를 굳히고 시장 점유율을 확대하기 위해 기업이 사용하는 주요 방법과 전략에는 신제품 출시, 연구개발비, 유통망 개척, M&A 등이 있습니다. 최근 동향 일부를 아래에 소개합니다.

최근 움직임

2021년 Biogen은 저분자 치료제 안티센스 올리고뉴클레오티드 Spinraza(누시넬센)를 개발했습니다.

연구 주요 특징

  • 보고서는 희소 신경질환 치료 시장 시장 규모, CAGR(2022년)을 기준년으로 한 추정, 예측(2023-2030년)을 제공합니다.
  • 보고서는 희귀 신경 질환 치료 시장 최신 동향 전망을 고객에게 제공합니다.
  • 조사 보고서는 다양한 부문/국가에 걸친 잠재 성장 기회를 밝혀내고 희귀 신경질환 치료 시장 매력적인 투자 제안 매트릭스를 설명합니다.
  • 전체 보고서는 신규 투자 기회, 기존 기업이 직면하는 과제, 희소 신경질환 치료 시장 지속하기 위한 성장 요인을 특정하고 있습니다
  • 희소 신경질환 치료 시장 규모, 예측, CAGR, 시장 역학 COVID-19 영향에 대해 조사범위 상세하게 논의하고 있습니다. COVID 후 희귀 신경 질환 치료 시장 자세한 전망도 다룹니다.
  • 보고서 사용자에게 희소 신경질환 치료 시장 종합적 인 견해를 제공하기 위해 희소 신경질환 치료 시장 경쟁 구도와 주요 혁신자 분석도 포함되어 있습니다.
  • 이 설문조사는 시장 규모, 성장률 및 매력에 따라 모든 산업 부문을 벤치마킹한 성장 전망 매핑 분석을 다룹니다.
  • 희귀 신경질환 치료 시장 사업을 전개하는 기업 약제 등급 재무 상황 및 전략 이니셔티브를 이해하는데 도움이 되는 주요 시장 진출기업을 특집한 상세한 기업 프로필을 제공합니다.
  • 또한 세계의 수준뿐만 아니라 지역 수준 시장에 관여하는 주요 진출기업 중요 인수 및 합병, 제휴 및 조인트 벤처, 신발매, 연구 개발, 지역 전개도 밝혔습니다.
  • 세계의 희소 신경질환 치료 시장 보고서는 주로 공급업체, 투자자, 신규 참가자, 유통업체, 금융 분석가 등 이 업계 다양한 이해관계자를 대상으로 합니다.

목차

제1장 희소 신경질환 치료 시장 주요 요약

  • 조사 범위

제2장 주요 요약

  • 시장 분석
  • 경쟁 인사이트

제3장 희소 신경질환 치료 주요 시장 동향

  • 희소 신경질환 치료 시장 성장 촉진 요인
  • 희소 신경질환 치료 시장 성장 억제 요인
  • 희소 신경질환 치료 시장 기회
  • 희소 신경질환 치료 시장 향후 동향

제4장 희소 신경질환 치료 산업 조사

  • PEST 분석
  • 포터의 5세력 분석
  • 성장 전망 맵핑
  • 규제 틀 분석

제5장 희소 신경질환 치료 시장 : COVID-19 영향 분석

  • COVID-19 이전 영향 분석
  • COVID-19 이후 영향 분석

제6장 희소 신경질환 치료 시장정세

  • 희소 신경질환 치료 시장 점유율 분석(2022년)
  • 주요 제조업체별 분석 데이터
    • 기존 기업 분석
    • 신흥기업 분석

제7장 희소 신경질환 치료 시장 - 약제 등급별

  • 주요 요약
    • 약물 등급별 부문 점유율 분석
    • 항우울제
    • 항정신병약제
    • 콜린에스테라아제억제제
    • 생물제제
    • 기타

제8장 희소 신경질환 치료 시장 - 질환 유형별

  • 주요 요약
    • 질병 유형별 부문 점유율 분석
    • 알츠하이머병
    • 나루코렙시
    • 경화증
    • 기타

제9장 희소 신경질환 치료 시장 - 용도별

  • 주요 요약
    • 용도별 부문 점유율 분석
    • 병원 및 진료소
    • 수술센터
    • 기타

제10장 희소 신경질환 치료 시장 - 지역별

  • 소개
  • 북미
    • 주요 요약
    • 북미 희소 신경질환 치료 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 주요 요약
    • 유럽 희소 신경질환 치료 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 주요 요약
    • 아시아태평양 희소 신경질환 치료 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 주요 요약
    • 라틴아메리카 희소 신경질환 치료 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 주요 요약
    • 중동 및 아프리카 희소 신경질환 치료 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제11장 주요 벤더 분석-희소 신경질환 치료 산업

  • 경쟁 대시보드
  • 기업 프로필
    • Biogen Inc.
    • Genzyme Corporation
    • Novartis International AG
    • Roche Holding AG
    • Pfizer Inc.
    • Johnson&Johnson
    • AbbVie Inc.
    • Merck&Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Alexion Pharmaceuticals, Inc.
    • Amgen Inc.
    • Vertex Pharmaceuticals Incorporated
    • Ionis Pharmaceuticals, Inc.
    • Sarepta Therapeutics, Inc.

제12장 애널리스트 전망

NJH 23.08.21

REPORT HIGHLIGHT

Rare Neurological Disease Treatment Market size was valued at USD 9,435.3 Million in 2022, expanding at a CAGR of 7.7% from 2023 to 2030.

The treatment of rare neurological diseases varies depending on the specific condition and its underlying cause. Thus, it becomes essential to consult with a healthcare professional or specialist for treatment of these neurological diseases.

Rare Neurological Disease Treatment Market- Market Dynamics:

Increasing research and development activities is expected to propel the rare neurological disease treatment demand.

Collaboration among researchers, medical professionals, pharmaceutical firms, and patient advocacy organizations has been essential in promoting the creation of medicines for uncommon neurological illnesses. Patient advocacy groups promote research, help, and create awareness, which improves patient outcomes and treatment alternatives. Technology advancements like next-generation sequencing, high-throughput screening, and gene editing methods have sped up the search for and development of viable treatments for uncommon neurological illnesses. Researchers may now identify therapeutic targets, create brand-new medications, and personalize therapy strategies thanks to these technologies.

The biological genetic and molecular developments involved in uncommon neurological illnesses are now better understood because of developments in genomics and molecular biology. This information has created new possibilities for precision medicine and targeted therapeutics.

Rare Neurological Disease Treatment Market- Key Insights:

  • As per the analysis shared by our research analyst, the global Rare Neurological Disease Treatment market is estimated to grow annually at a CAGR of around 7.7% over the forecast period (2023-2030)
  • The Rare Neurological Disease Treatment industry is projected to grow at a significant rate due to the growing focus on animal health and nutrition.
  • Based on Disease Type, Alzheimer's disease segment was predicted to show maximum market share in the year 2022.
  • Based on Application, hospital pharmacies segment is expected to hold significant market share by 2030.
  • Based on Drug Class segmentation, anti-depressants segment was the leading in 2022
  • On the basis of region, North America was the leading revenue generator in 2022.

Rare Neurological Disease Treatment Market- Segmentation Analysis:

The Global Rare Neurological Disease Treatment Market is segmented on the basis of Drug Class, Disease Type, Application, and Region.

The market is divided into five categories based on Drug Class: Anti-depressants, anti-psychotics, cholinesterase inhibitors, biologics, and others. The Anti-depressants segment dominates the market. Growing demand for anti-depressants for disease care is contributing to market growth.

The market is divided into four categories based on Disease Type: Alzheimer's disease, narcolepsy, sclerosis, and others. The Alzheimer's disease segment dominates the market. Growing prevalence of Alzheimer disorders which is influencing the market growth.

The market is divided into three categories based on Application: hospitals & clinics, surgical centers, and others. The hospitals pharmacies segment dominates the market. The rising number of neurological disease treatment at hospital level is increasing the segment growth.

Rare Neurological Disease Treatment Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Rare Neurological Disease Treatment Market- Competitive Landscape:

Owing to the rising prevalence of neurological disorders, which influence the rare neurological disease treatment market. Several distribution channels, including corporate websites, and Disease Types, are used by businesses to sell their solutions & products. Products compete on various factors, such as technology, product creation, and marketing. reputation, and availability. Some of the primary techniques, and strategies used by corporations to consolidate their reach and grow their market share include new product launches, R&D expenditure, developing its distribution network and mergers & acquisitions. Some of the recent developments are mentioned below.

Recent Developments:

In 2021, Biogen developed Spinraza (nusinersen), an antisense oligonucleotide, for the treatment of small molecular therapies.

Key features of the study:

  • This proposed research study on Rare Neurological Disease Treatment market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
  • The report provides the client the latest up-to-date and trending insights about the Rare Neurological Disease Treatment market.
  • The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Rare Neurological Disease Treatment market
  • The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Rare Neurological Disease Treatment market
  • Impact of COVID-19 on Rare Neurological Disease Treatment market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Rare Neurological Disease Treatment market post-COVID will also be covered.
  • In order to give the users of this report a comprehensive view on the Rare Neurological Disease Treatment market, we have also included competitive landscape and key innovator analysis for the Rare Neurological Disease Treatment market.
  • The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
  • The report offers detailed company profiling featuring major market participants which will help users to understand their financial in Drug Class and strategic initiatives of players operating in the Rare Neurological Disease Treatment market.
  • In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
  • The global Rare Neurological Disease Treatment market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RARE NEUROLOGICAL DISEASE TREATMENT MARKET KEY PLAYERS

  • Biogen Inc.
  • Genzyme Corporation
  • Novartis International AG
  • Roche Holding AG
  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Vertex Pharmaceuticals Incorporated
  • Ionis Pharmaceuticals, Inc.
  • Sarepta Therapeutics, Inc.

GLOBAL RARE NEUROLOGICAL DISEASE TREATMENT MARKET, BY DRUG CLASS

  • Anti-depressants
  • Anti-psychotics
  • Cholinesterase inhibitors
  • Biologics
  • Others

GLOBAL RARE NEUROLOGICAL DISEASE TREATMENT MARKET, BY DISEASE TYPE

  • Alzheimer's disease
  • Narcolepsy
  • Sclerosis
  • Others

GLOBAL RARE NEUROLOGICAL DISEASE TREATMENT MARKET, BY APPLICATION

  • Hospitals & clinics
  • Surgical centers
  • Others

GLOBAL RARE NEUROLOGICAL DISEASE TREATMENT MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Rare Neurological Disease Treatment Market Overview

  • 1.1. Study Scope

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Rare Neurological Disease Treatment Market Snippet by Drug Class
    • 2.1.2. Rare Neurological Disease Treatment Market Snippet by Disease Type
    • 2.1.3. Rare Neurological Disease Treatment Market Snippet by Application
    • 2.1.4. Rare Neurological Disease Treatment Market Snippet by Country
    • 2.1.5. Rare Neurological Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Rare Neurological Disease Treatment Key Market Trends

  • 3.1. Rare Neurological Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Rare Neurological Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Rare Neurological Disease Treatment Market Opportunities
  • 3.4. Rare Neurological Disease Treatment Market Future Trends

4. Rare Neurological Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Rare Neurological Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Rare Neurological Disease Treatment Market Landscape

  • 6.1. Rare Neurological Disease Treatment Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Rare Neurological Disease Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 7.1.2. Anti-depressants
    • 7.1.3. Anti-psychotics
    • 7.1.4. Cholinesterase inhibitors
    • 7.1.5. Biologics
    • 7.1.6. Others

8. Rare Neurological Disease Treatment Market - By Disease Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease Type, 2022 & 2030 (%)
    • 8.1.2. Alzheimer's disease
    • 8.1.3. Narcolepsy
    • 8.1.4. Sclerosis
    • 8.1.5. Others

9. Rare Neurological Disease Treatment Market - By Application

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Disease Type, 2022 & 2030 (%)
    • 9.1.2. Hospital & clinics
    • 9.1.3. Surgical centers
    • 9.1.4. Others

10. Rare Neurological Disease Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Rare Neurological Disease Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Rare Neurological Disease Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Rare Neurological Disease Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Rare Neurological Disease Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Rare Neurological Disease Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Disease Type, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Application, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Rare Neurological Disease Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Biogen Inc.
    • 11.2.2. Genzyme Corporation
    • 11.2.3. Novartis International AG
    • 11.2.4. Roche Holding AG
    • 11.2.5. Pfizer Inc.
    • 11.2.6. Johnson & Johnson
    • 11.2.7. AbbVie Inc.
    • 11.2.8. Merck & Co., Inc.
    • 11.2.9. Teva Pharmaceutical Industries Ltd.
    • 11.2.10. Takeda Pharmaceutical Company Limited
    • 11.2.11. Alexion Pharmaceuticals, Inc.
    • 11.2.12. Amgen Inc.
    • 11.2.13. Vertex Pharmaceuticals Incorporated
    • 11.2.14. Ionis Pharmaceuticals, Inc.
    • 11.2.15. Sarepta Therapeutics, Inc.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제